Ovarian Cancer Clinical Trial
Official title:
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Verified date | April 2024 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434 in combination with anti-PD-1 (Part 1B) and dose expansion (Part 2). Part 2 Dose Combination Expansion will enroll participants into 3 cohorts at doses determined from Part 1B in order to further evaluate the safety of PF-06940434 in combination with anti-PD-1.
Status | Active, not recruiting |
Enrollment | 85 |
Est. completion date | August 30, 2024 |
Est. primary completion date | August 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histological or cytological diagnosis of SCCHN, RCC (clear cell and papillary cell), ovarian, gastric, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma, or urothelial cancer. Part 2: - Arm A SCCHN: - Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx. - PDL-1 expression positive and CPS =1. No prior systemic therapy administered in the recurrent or metastatic setting (except for systemic therapy given as part of a multimodal treatment for locally advanced disease). - Arm B RCC (clear cell): - 1 or 2 prior lines of therapy including PD-L1/PD-1 immunotherapy in combination or sequentially with antiangiogenic directed treatment - Adequate bone marrow, kidney and liver function. - Performance status of 0 or 1. Exclusion Criteria: - Participant disease status is suitable for local therapy administered with curative intent. - Hypertension that cannot be controlled by medications. - Active or prior autoimmune disease - Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) Hepatitis B, Hepatitis C, and known Human Immunodeficiency Virus infection or Acquired Immunodeficiency Syndrome-related illness |
Country | Name | City | State |
---|---|---|---|
Australia | Liverpool Hospital | Liverpool | New South Wales |
Australia | Southern Medical Day Care Centre | Wollongong | New South Wales |
Korea, Republic of | Asan Medical Center | Seoul | Seoul-teukbyeolsi [seoul] |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul | |
Slovakia | Narodny ustav srdcovych a cievnych chorob, a.s. | Bratislava | |
Slovakia | Onkologicky ustav sv. Alzbety, s.r.o. | Bratislava | |
Slovakia | Univerzitna nemocnica Bratislava | Bratislava | |
Slovakia | MR Poprad s.r.o. | Komárno | |
Slovakia | KARDIO, s.r.o. | Poprad | |
Slovakia | MR Poprad s.r.o. | Poprad | |
Slovakia | Nemocnica Poprad a.s. | Poprad | |
Slovakia | Nemocnica Poprad a.s. | Poprad | |
Slovakia | POKO Poprad, s.r.o., Ambulancia klinickej onkologie | Poprad | |
Taiwan | National Cheng Kung University Hospital | Tainan | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei | |
United States | Greenebaum Comprehensive Cancer Center | Baltimore | Maryland |
United States | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland |
United States | Siteman Cancer Center - West County | Creve Coeur | Missouri |
United States | Duke Univ. Medical Center/Duke Cancer Center | Durham | North Carolina |
United States | Investigational Chemotherapy Service | Durham | North Carolina |
United States | Siteman Cancer Center - North County | Florissant | Missouri |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Monter Cancer Center | Lake Success | New York |
United States | R.J. Zuckerberg Cancer Center | Lake Success | New York |
United States | Ronald Reagan UCLA Medical Center | Los Angeles | California |
United States | UCLA Hematology Oncology | Los Angeles | California |
United States | UCLA Hematology/Oncology | Los Angeles | California |
United States | Barnes-Jewish Hospital | Saint Louis | Missouri |
United States | Siteman Cancer Center - North County | Saint Louis | Missouri |
United States | Siteman Cancer Center - South County | Saint Louis | Missouri |
United States | Washington University School of Medicine Siteman Cancer Center | Saint Louis | Missouri |
United States | Siteman Cancer Center - St. Peters | Saint Peters | Missouri |
United States | NEXT Oncology | San Antonio | Texas |
United States | UCLA Hematology/Oncology | Santa Monica | California |
United States | HonorHealth Research Institute | Scottsdale | Arizona |
United States | HonorHealth Scottsdale Shea Medical Center | Scottsdale | Arizona |
United States | Scottsdale Healthcare Hospitals DBA HonorHealth | Scottsdale | Arizona |
United States | Virginia G. Piper Cancer Pharmacy | Scottsdale | Arizona |
United States | Fred Hutchinson Cancer Center | Seattle | Washington |
United States | University of Washington Medical Center | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Australia, Korea, Republic of, Slovakia, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding | Baseline up to 28 Days (Cycle 1) | ||
Primary | Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities | Baseline up to approximately 24 months | ||
Primary | Number of Participants With Adverse Events (AEs) According to Severity | Baseline up to approximately 24 months | ||
Primary | Number of Participants With Adverse Events (AEs) According to Seriousness | Baseline up to up to approximately 24 months | ||
Primary | Number of Participants With Adverse Events (AEs) by Relationship | Baseline up to approximately 24 months | ||
Primary | Progression-Free Survival (PFS) for Dose Expansion | The period from study entry until disease progression, death or date of last contact. | Baseline up to 24 Months | |
Primary | Objective Response Rate - Percentage of Participants With Objective Response in Dose Expansion | Baseline up to 24 months | ||
Primary | Duration of Response (DR) for Dose Expansion | Baseline up to 24 Months | ||
Secondary | PF-06940434 after multiple doses PK parameters (Cmax). | Maximum observed plasma concentration of PF-06940434. | Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days). | |
Secondary | Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434. | Time zero extrapolated to the last quantifiable time point prior to the next dose. | Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days). | |
Secondary | Systemic Clearance (CL) | CL is a quantitative measure of the rate at which a drug substance is removed from the body. | Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days). | |
Secondary | Volume of Distribution (Vd) | Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days). | ||
Secondary | Incidence and titers of anti-drug antibodies (ADA) against PF-06940434. | Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days). | ||
Secondary | Incidence and titers of neutralizing antibodies (NAb) against PF-06940434. | Titers of neutralizing antibodies (NAb) against PF-06940434. | Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days). | |
Secondary | PK parameters of PF-06940434 and PF-06801591 (Cmax). | Maximum observed plasma concentration after multiple doses of PF-06940434 and PD-1 (PF-06801591). | Pre-dose on Cycle 1 Day 1 and on day 15 of Cycle 1; Day 1 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days) | |
Secondary | Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434 and PF-06801591. | Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434 and PF-06801591. | Pre-dose on Cycle 1 Day 1 and on day 15 of Cycle 1; Day 1 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days) | |
Secondary | Characterize the multiple dose PK of PF-06940434 following intravenous administration in combination with PF-06801591. | Maximum observed plasma concentration of PF-06940434. | Cycle 4 Day 1 (each cycle is 28 days) | |
Secondary | Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434. | Time zero extrapolated to the last quantifiable time point prior to the next dose. | Cycle 4 Day 1 (each cycle is 28 days) | |
Secondary | Number of participants with increased T-cells after PF-06940434 treatment. | Pre-dose on Day 1 of Cycle 1; pre-dose on Day 1 of Cycles 2 and 3 (each cycle is 28 days) | ||
Secondary | Progression-Free Survival (PFS) for Dose Expansion | The period from study entry until disease progression, death or date of last contact. | Baseline to measured progression (up to approximately 24 months) | |
Secondary | Duration of Response (DR) | Baseline up to approximately 24 Months | ||
Secondary | Number of Participants With Objective Response for Dose Expansion portion | Baseline up to 24 months | ||
Secondary | Disease Control Rate (DCR) | DCR is defined as the percent of participants with a confirmed complete response (CR), partial response (PR) or stable disease (SD) according to RECIST 1.1. | Every 8 weeks from the time of enrollment up to 2 years | |
Secondary | Trough concentrations of PF-06940434 and PF-06801591 in Dose Expansion | Day 1 of Cycle 1 though 4, Day 1 of every 2 Cycles starting from Cycle 5 up to 24 months (each cycle is 28 days). For Part 2 Cohort 3, Day 1 of Every Cycle (each cycle is 21 days) | ||
Secondary | Plasma Decay Half-Life (t1/2) | Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. | Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days] | |
Secondary | Incidence and titers of anti-drug antibodies (ADA) against PF-06801591 in Dose Finding and Dose Expansion | Incidence and titers of anti-drug antibodies (ADA) against PF-06801591. | Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days]. | |
Secondary | Incidence and titers of neutralizing antibodies (NAb) against PF-06801591 in Dose Finding and Dose Expansion. | Incidence and titers of neutralizing antibodies (NAb) against PF-06801591. | Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days]. | |
Secondary | Overall Survival | The period from study entry until death or date of last contact (24 months) | From baseline to up to 2 years after last dose of study drug |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |